摘要
目的 探讨长链非编码RNA FOXD2-AS1在评估临床胶质瘤患者预后方面的意义,并研究FOXD2-AS1对胶质瘤细胞增殖和侵袭能力的影响。方法 收集2012年1月至2015年1月间空军军医大学唐都医院神经外科收治的53例胶质瘤患者的标本组织,同期取脑外伤行开颅手术的30例患者的正常脑组织作为对照组。qRT-PCR法检测两组患者组织中FOXD2-AS1的表达。然后采用χ;检验分析FOXD2-AS1的表达水平与胶质瘤患者临床参数资料之间的关系,采用Kaplan-Meier法进行生存分析并用Log-rank检验。采用单因素和多因素分析观察影响胶质瘤患者预后的因素。应用qRT-PCR法检测FOXD2-AS1在U251人胶质瘤细胞株和HEB细胞中的表达水平。利用人工合成的shRNA在U251细胞中对FOXD2-AS1表达进行干扰,采用MTT实验和Transwell实验评估U251细胞的增殖和侵袭能力。结果 与正常脑组织相比,FOXD2-AS1在胶质瘤组织中的表达显著上调(P<0.001),且与Ⅰ~Ⅱ级胶质瘤相比,Ⅲ~Ⅳ级胶质瘤中FOXD2-AS1的表达显著上调(P=0.001 2)。χ;检验分析结果显示,胶质瘤组织中FOXD2-AS1的高表达与患者的KPS评分(P=0.022)、WHO分级(P=0.024)、患者术后复发(P=0.042)有关。生存分析结果提示,与低表达组相比,高表达组患者5年生存率明显降低(P=0.002 3)。此外,单因素及多因素分析结果证实,高FOXD2-AS1表达、KPS评分<80、高WHO分级以及术后复发均为影响胶质瘤患者预后的独立风险因素(P分别为0.002,0.010,0.007,0.004)。在体外实验中发现,较之于HEB细胞,FOXD2-AS1在胶质瘤细胞株中显著过表达(P=0.005)。MTT实验和Transwell实验结果表明转染sh-FOXD2-AS1可降低U251细胞的增殖和侵袭能力(P<0.05)。结论 FOXD2-AS1在胶质瘤中表达显著增高,并与胶质瘤患者生存率、预后密切相关,抑制其表达可降低胶质瘤细胞的增殖和侵袭能力,其有望成为潜在的治疗靶点。
Objective To investigate the significance of long non-coding RNA FOXD2-AS1 in evaluation of the prognosis of glioma patients, and the effect of FOXD2-AS1 on the proliferation and invasion abilities of glioma cells. Methods Tissue samples from 53 glioma patients were collected in the department of neurosurgery in Tangdu Hospital, Air Force Medical University from January 2012 to January 2015, and normal brain tissues from 30 patients undergoing craniotomy for brain injury were used as control group. FOXD2-AS1 expression in tissues was detect by qRT-PCR. Then χ;test was used to analyze the relationships between FOXD2-AS1 expression level and clinical parameters of patients with glioma. Kaplan-Meier method and Log-rank test were used for the survival analysis. Univariate and multivariate analysis were performed to analyze the prognostic factors of glioma patients. The expression level of FOXD2-AS1 in U251 human glioma cell line and HEB cells was detected by qRT-PCR. A synthetic shRNA was used to interfere with FOXD2-AS1 expression in U251 cells, and the proliferation and invasion abilities of U251 cells were evaluated by MTT assay and Transwell assay, respectively. Results The expression of FOXD2-AS1 in glioma tissues was significantly up-regulated compared with normal brain tissues(P<0.001). Compared with grade Ⅰ-Ⅱ glioma, FOXD2-AS1 expression was significantly up-regulated in grade Ⅲ-Ⅳ glioma(P=0.001 2). The χ;test analysis showed that the high level of FOXD2-AS1 expression in glioma tissues was correlated with KPS score(P=0.022), WHO grade(P=0.024), postoperative recurrence(P=0.042), and the survival analysis indicated that the 5-year survival rate was significantly lower in patients with high expression of FOXD2-AS1 than that of patients with low expression(P=0.002 3). The univariate and multivariate analysis confirmed that higher FOXD2-AS1 expression, KPS score<80, high WHO grade and postoperative recurrence were independent risk factors for the prognosis of glioma patients(P=0.002, 0.010, 0.007, 0.00
作者
吴楠
孙树凯
秦彦昌
于庆伟
张百平
WU Nan;SUN Shukai;QIN Yanchang;YU Qingwei;ZHANG Baiping(Department of Neurosurgery,Xi’an Daxing Hospital,Xi’an 710016,China;Department of Neurosurgery,Tangdu Hospital,Air Force Military Medical University)
出处
《山西医科大学学报》
CAS
2022年第3期287-292,共6页
Journal of Shanxi Medical University
